• 1. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenols Tyrosols and derivatives

Recent Advances in the Study of O-Desmethyl Metoprolol (CAS: 62572-94-5)

O-Desmethyl Metoprolol (CAS: 62572-94-5), a major metabolite of the widely used beta-blocker metoprolol, has garnered significant attention in recent pharmacological and clinical research. This compound plays a crucial role in understanding the pharmacokinetics and pharmacodynamics of metoprolol, particularly in personalized medicine and drug metabolism studies. Recent studies have focused on its therapeutic implications, metabolic pathways, and potential applications in cardiovascular diseases.

A 2023 study published in the Journal of Clinical Pharmacology elucidated the enzymatic pathways involved in the formation of O-Desmethyl Metoprolol, highlighting the role of CYP2D6 polymorphisms in its variable plasma concentrations among different patient populations. The research demonstrated that individuals with reduced CYP2D6 activity exhibit higher plasma levels of metoprolol and lower levels of O-Desmethyl Metoprolol, which has significant implications for dosing regimens and therapeutic outcomes.

Another groundbreaking study in the European Journal of Pharmaceutical Sciences (2024) investigated the potential of O-Desmethyl Metoprolol as a biomarker for assessing CYP2D6 activity in vivo. The researchers developed a sensitive LC-MS/MS method for simultaneous quantification of metoprolol and its metabolites, including O-Desmethyl Metoprolol, in human plasma. This method showed high precision and accuracy, making it valuable for clinical pharmacokinetic studies and therapeutic drug monitoring.

Recent advances in analytical chemistry have also enabled more detailed characterization of O-Desmethyl Metoprolol. A 2024 paper in Analytical and Bioanalytical Chemistry reported the crystal structure of O-Desmethyl Metoprolol (62572-94-5) and its unique physicochemical properties, which could inform future drug design and formulation strategies. The study revealed important insights into the compound's stability and solubility profiles under various physiological conditions.

From a clinical perspective, ongoing research is exploring the potential cardiovascular effects of O-Desmethyl Metoprolol itself. While traditionally considered an inactive metabolite, preliminary data from cell culture studies suggest it may possess some β-adrenergic receptor binding activity, though significantly weaker than the parent compound. These findings, published in Cardiovascular Pharmacology Open Access (2023), warrant further investigation into the pharmacological significance of this metabolite.

The pharmaceutical industry has shown growing interest in O-Desmethyl Metoprolol as reference standards and analytical markers. Several manufacturers have recently developed high-purity (>98%) O-Desmethyl Metoprolol standards (CAS: 62572-94-5) to support drug development and regulatory compliance. These products are becoming increasingly important for bioequivalence studies and generic drug development programs.

Future research directions for O-Desmethyl Metoprolol include exploring its potential role in drug-drug interactions, particularly with other CYP2D6 substrates, and investigating its utility as a phenotypic marker for CYP2D6 activity in precision medicine approaches. The compound continues to serve as an important tool for understanding interindividual variability in drug response and optimizing beta-blocker therapy for cardiovascular diseases.

• 81024-42-2((S)-Metoprolol)
• 5790-46-5(1-Isopropylamino-3-(p-tolyloxy)-2-propanol)
• 959787-96-3(rac Metoprolol-d7)
• 81024-43-3((R)-Metoprolol)
• 51384-51-1(Metoprolol)
• 56392-16-6(a-Hydroxy Metoprolol (Mixture of Diastereomers))
• 29277-73-4(2-4-(2RS)-2-Hydroxy-3-(1-methylethyl)aminopropoxyphenylacetonitrile; (Atenolol Impurity H))
• 37350-58-6(Metoprolol)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)